Chronic Obstructive Pulmonary Disease Markers and Prognosis
NCT ID: NCT00605540
Last Updated: 2014-09-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
133 participants
OBSERVATIONAL
2008-01-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Hospital Readmission for Chronic Obstructive Pulmonary Disease Patients
NCT06348966
A Cohort of Patients With Chronic Pulmonary Disease
NCT04050943
Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
NCT03400839
Prevalence of Chronic Obstructive Pulmonary Disease in the Portuguese Population
NCT06523257
Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study
NCT05681364
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study COPD population
Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Inability to perform pulmonary function and exercise tolerance tests
* Recent myocardial infarction or unstable angina
* Congestive heart failure: class III/IV
40 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UPECLIN HC FM Botucatu Unesp
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Irma de Godoy
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irma de Godoy, PhD, MD
Role: STUDY_CHAIR
Botucatu School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Botucatu School of Medicine
Botucatu, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ferrari R, Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013 Feb 20;14(1):24. doi: 10.1186/1465-9921-14-24.
Ferrari R, Tanni SE, Caram LM, Naves CR, Godoy I. Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2011 Dec 9;9:112. doi: 10.1186/1477-7525-9-112.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
upeclin/HC/FMB-Unesp-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.